Autres langues Allogene Therapeutics, Inc.

Actions

ALLO

US0197701065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
1,630 ^USD	-1,21%		-3,55%	+18,98%

14/09	L'action Cellectis chute après son repositionnement stratégique dans l'édition génomique in vivo	MT
09/09	Transcript : Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM

Autres langues

14/09	Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company
02/09	Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026
02/09	Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Executive Vice President and Principal Financial Officer, Effective November 6, 2026
02/09	Allogene Therapeutics CFO Geoffrey Parker to Retire
02/09	Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
31/08	Allogene Therapeutics Announces Participation in September Investor Conference
13/08	Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
12/08	Allogene Therapeutics Q2 Loss Narrows
12/08	Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss
12/08	Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Allogene Therapeutics: Q2 Earnings Snapshot
12/08	Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL
12/08	Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
04/08	Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
30/07	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Cemacabtagene Ansegedleucel as First-Line Consolidation Therapy for Large B-Cell Lymphoma
29/07	Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations
29/07	Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma
29/07	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
15/07	Allogene Therapeutics Publishes Phase 1 Results of Allo-316 in Journal of Clinical Oncology
15/07	Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
30/05	Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.
30/05	Certain Stock Options of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.
30/05	Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.
28/05	Allogene Therapeutics CEO David Chang Steps Down
28/05	Allogene Therapeutics announces planned CEO succession